WCLC 2022 Conference Coverage


 

WCLC 2022 on the Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ Disease

78 views
August 18, 2022
Comments 0
Login to view comments. Click here to Login